Literature DB >> 33690604

Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease.

Tanu Rana1, Olga Y Korolkova1, Girish Rachakonda2, Amanda D Williams3, Alexander T Hawkins4, Samuel D James5,6, Amos M Sakwe7, Nian Hui8, Li Wang8, Chang Yu8, Jeffrey S Goodwin1, Michael G Izban5, Regina S Offodile9, Mary K Washington10, Billy R Ballard5, Duane T Smoot11, Xuan-Zheng Shi12, Digna S Forbes5, Anil Shanker1, Amosy E M'Koma1,4,5.   

Abstract

Evidence link bacterial enterotoxins to apparent crypt-cell like cells (CCLCs), and Alpha Defensin 5 (DEFA5) expansion in the colonic mucosa of Crohn's colitis disease (CC) patients. These areas of ectopic ileal metaplasia, positive for Paneth cell (PC) markers are consistent with diagnosis of CC. Retrospectively, we: 1. Identified 21 patients with indeterminate colitis (IC) between 2000-2007 and were reevaluation their final clinical diagnosis in 2014 after a followed-up for mean 8.7±3.7 (range, 4-14) years. Their initial biopsies were analyzed by DEFA5 bioassay. 2. Differentiated ulcer-associated cell lineage (UACL) analysis by immunohistochemistry (IHC) of the CC patients, stained for Mucin 6 (MUC6) and DEFA5. 3. Treated human immortalized colonic epithelial cells (NCM460) and colonoids with pure DEFA5 on the secretion of signatures after 24hr. The control colonoids were not treated. 4. Treated colonoids with/without enterotoxins for 14 days and the spent medium were collected and determined by quantitative expression of DEFA5, CCLCs and other biologic signatures. The experiments were repeated twice. Three statistical methods were used: (i) Univariate analysis; (ii) LASSO; and (iii) Elastic net. DEFA5 bioassay discriminated CC and ulcerative colitis (UC) in a cohort of IC patients with accuracy. A fit logistic model with group CC and UC as the outcome and the DEFA5 as independent variable differentiator with a positive predictive value of 96 percent. IHC staining of CC for MUC6 and DEFA5 stained in different locations indicating that DEFA5 is not co-expressed in UACL and is therefore NOT the genesis of CC, rather a secretagogue for specific signature(s) that underlie the distinct crypt pathobiology of CC. Notably, we observed expansion of signatures after DEFA5 treatment on NCM460 and colonoids cells expressed at different times, intervals, and intensity. These factors are key stem cell niche regulators leading to DEFA5 secreting CCLCs differentiation 'the colonic ectopy ileal metaplasia formation' conspicuously of pathogenic importance in CC.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33690604      PMCID: PMC7942995          DOI: 10.1371/journal.pone.0246393

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  59 in total

Review 1.  Defensins in Viral Infection and Pathogenesis.

Authors:  Mayumi K Holly; Karina Diaz; Jason G Smith
Journal:  Annu Rev Virol       Date:  2017-07-17       Impact factor: 10.431

2.  Identification of pathologic features associated with "ulcerative colitis-like" Crohn's disease.

Authors:  Samuel D James; Paul E Wise; Tania Zuluaga-Toro; David A Schwartz; M Kay Washington; Chanjuan Shi
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 3.  Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.

Authors:  Warren Strober; Ivan J Fuss
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

4.  Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways.

Authors:  Porfirio Nava; Stefan Koch; Mike G Laukoetter; Winston Y Lee; Keli Kolegraff; Christopher T Capaldo; Neal Beeman; Caroline Addis; Kirsten Gerner-Smidt; Irmgard Neumaier; Arne Skerra; Linheng Li; Charles A Parkos; Asma Nusrat
Journal:  Immunity       Date:  2010-03-18       Impact factor: 31.745

5.  Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.

Authors:  Amosy E M'Koma; Erin H Seeley; Mary K Washington; David A Schwartz; Roberta L Muldoon; Alan J Herline; Paul E Wise; Richard M Caprioli
Journal:  Inflamm Bowel Dis       Date:  2010-08-30       Impact factor: 5.325

Review 6.  The role and advances of immunomodulator therapy for inflammatory bowel disease.

Authors:  Ole Haagen Nielsen; Mehmet Coskun; Casper Steenholdt; Gerhard Rogler
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-08-07       Impact factor: 3.869

Review 7.  Interferon-gamma regulation of intestinal epithelial permeability.

Authors:  Cécile Beaurepaire; David Smyth; Derek M McKay
Journal:  J Interferon Cytokine Res       Date:  2009-03       Impact factor: 2.607

Review 8.  Paneth Cells during Viral Infection and Pathogenesis.

Authors:  Mayumi K Holly; Jason G Smith
Journal:  Viruses       Date:  2018-04-26       Impact factor: 5.048

9.  Implications of the colonic deposition of free hemoglobin-α chain: a previously unknown tissue by-product in inflammatory bowel disease.

Authors:  Jeremy N Myers; Michael W Schäffer; Olga Y Korolkova; Amanda D Williams; Pandu R Gangula; Amosy E M'Koma
Journal:  Inflamm Bowel Dis       Date:  2014-09       Impact factor: 7.290

Review 10.  Costs in inflammatory bowel diseases.

Authors:  Paweł W Petryszyn; Izabela Witczak
Journal:  Prz Gastroenterol       Date:  2016-02-11
View more
  2 in total

Review 1.  Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview.

Authors:  Amosy Ephreim M'Koma
Journal:  Medicina (Kaunas)       Date:  2022-04-21       Impact factor: 2.948

Review 2.  Patient-derived rectal cancer organoids-applications in basic and translational cancer research.

Authors:  Yumeng Yan; Io Hong Cheong; Peizhan Chen; Xiaoguang Li; Xianli Wang; Hui Wang
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.